Business, energy, technology, markets and global industry news from Business News Today

AbelZeta Pharma

PharmaDeviceNews AbelZeta Pharma
AbelZeta’s FDA-cleared registrational Phase II trial will evaluate the investigational dual-target CAR-T therapy C-CAR168 in patients with refractory lupus nephritis. Representative image.
Pharma & Biotech

Can AbelZeta turn a tiny lupus dataset into a registrational CAR-T breakthrough?

AbelZeta's FDA-cleared Phase II C-CAR168 trial tests whether dual-target CAR-T can deliver durable renal responses in refractory lupus nephritis.

Read More
Laboratory research into AbelZeta Pharma’s C-CAR031 armored GPC3 CAR-T therapy highlights the emerging potential and durability challenges of cellular treatment for advanced hepatocellular carcinoma. Representative image.
Pharma & Biotech

AbelZeta and AstraZeneca study identifies GPC3 loss as a potential C-CAR031 resistance mechanism

AbelZeta’s C-CAR031 study shows a 44.4% response rate in advanced liver cancer, but durability and resistance remain key tests.

Read More
Pharma & Biotech

What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer

AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.

Read More